RBC Capital Reiterates Outperform on Medtronic, Maintains $118 Price Target

Benzinga Newsdesk www.benzinga.com Negative 83.6%

Neg 83.6% Neu 0% Pos 0%

RBC Capital analyst Kendall Au reiterates Medtronic (NYSE:MDT) with a Outperform and maintains $118 price target.

Comments

No comments yet. Be the first!